TS-064191 — The emergence of SARS-CoV-2 variants poses a significant challenge to existing COVID-19 vaccines, necessitating the development of a more durable and broadly protective solution. Current vaccines show reduced efficacy over time and struggle against Variants of Concern (VoCs) such as Omicron. Addre…

TS-064189 — The Need The current global landscape demands innovative solutions to address the urgent need for a safe and efficacious SARS-CoV-2 vaccine, particularly for the vulnerable population of infants and children under 12 years old. Existing vaccines face challenges in terms of durability, cost, and sta…

TS-062261 — The Need: Addressing the Zika Virus Outbreak The Zika virus outbreak, which started in South America and quickly became a global public health issue, has led to severe neurological disorders, birth defects, and other health complications in affected populations. Despite efforts to combat the virus,…

TS-062231 — The Need: Addressing the Urgent Need for a Safe and Effective SARS-CoV-2 Vaccine for Infants and Children The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has brought about significant economic, emotional, and public health challenges worldwide. The pressing dema…

TS-062213 — The Need: Preventing Respiratory Syncytial Virus (RSV) Infection and Disease Respiratory Syncytial Virus (RSV) is a highly prevalent and dangerous pathogen responsible for significant morbidity and mortality, particularly in infants, young children, and immunocompromised individuals. Despite its gl…

TS-037753 — A method to create vaccines for pneumoviruses, using recombinant viruses.

TS-037675 — Novel method of using live attenuated vaccines to prevent infection of hMVP.

TS-037664 — A live recombinant vesicular stomatitis virus (VSV)-vector vaccine composition for human norovirus.

TS-037299 — Recombinant vesicular stomatitis virus (rVSV) vaccines to fight against respiratory syncytial virus (RSV) infections.